We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
Consensus vs. actual, and revenue trend
Rating & price-target changes
Stored first · Google News · Yahoo Finance (English)
Recon: FDA denies Hengrui-Elevar liver cancer drug for the third time; GSK to pursue FDA nod for Jemperli for rectal cancer - RAPS
Recon: FDA denies Hengrui-Elevar liver cancer drug for the third time; GSK to pursue FDA nod for Jemperli for rectal cancer RAPS
GSK's Jemperli meets main goal in mid-stage rectal cancer trial - Reuters
GSK's Jemperli meets main goal in mid-stage rectal cancer trial Reuters
GSK's New Severe Asthma Med: 'Carry On, With Fewer Attacks' 07/14/2026 - MediaPost
GSK's New Severe Asthma Med: 'Carry On, With Fewer Attacks' 07/14/2026 MediaPost
GSK posts positive interim results for Jemperli in rectal cancer - The Pharma Letter
GSK posts positive interim results for Jemperli in rectal cancer The Pharma Letter
GSK plc (GSK) executives add stock via Share Reward Plan and dividend reinvestment - Stock Titan
GSK plc (GSK) executives add stock via Share Reward Plan and dividend reinvestment Stock Titan
GSK to seek FDA approval for Jemperli in small but high-profile cancer use after phase 2 win - Fierce Pharma
GSK to seek FDA approval for Jemperli in small but high-profile cancer use after phase 2 win Fierce Pharma
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 07. 28. | After market close (AMC) | — | — | — | $8.25B | — | Scheduled |
No research actions to show.
Price data
No holdings data to show.